New York81°

New York81°

May 30, 2020 CONTACT

CBD Archives - Hemp Market Report

StaffStaffMay 22, 2020


Biota Biosciences

Biota Biosciences is voluntarily recalling the following lots in the table below of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables to the customer level. These injectable products are being recalled because they were marketed without FDA approval. The product’s claims on the company’s website make these products unapproved new drugs. Further, the products are misbranded because the labeling fails to bear adequate directions for use.

Product Name Strength(mg)
Multiple Dose Vial Size Lot Expiration
Cannabidiol(CBD) Complex 4 10 mL 2H071219P 07/12/2021
50 10 mL 10102019P 10/10/2021
Curcumin Complex 4 10 mL 2H071219CCD 07/12/2021
50 10 mL 0712019CCD 07/12/2021
Cannabidiol + Curcumin 50 10 mL 10102019PC 10/10/2021

Risk Statement: Unapproved new drugs injected into the bloodstream for which safety and efficacy have not been established could pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Biota Biosciences has not received any reports of adverse events related to this recall.

Cannabidiol (CBD) Complex was marketed to suppress pain and aid in the detoxification processes as a promising therapeutic for a wide array of disorders such as epilepsy, including many challenging neuropathy conditions. Curcumin Complex was marketed as a potent anti-inflammatory and antioxidant that may also help improve symptoms of depression and arthritis. Cannabidiol + Curcumin was marketed as a more efficient therapeutic effect. The product was sold to certified practitioners who further administer to customers. The product is packaged in 10 mL sterile vials. Products were distributed Nationwide in the USA and one consignee in New Zealand.

Water Soluble 4mg/10m products can be identified by the labels below.

Water Soluble 50mg/10m products can be identified by the labels below.

Biota Biosciences is notifying its distributors and customers by email and is arranging for return of all recalled products. Practitioners or consumers that have a product which is being recalled should stop using the product and return to the place of purchase.

Consumers with questions regarding this recall can contact Biota Biosciences by phone number at (866) 996-2293 Monday to Friday 8:00 am to 4:00 pm PST or by e-mail at Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Summit Labs

Summitt Labs is voluntarily recalling Batch#730 Lot#K018 of KORE ORGANIC Watermelon CBD Oil Tincture, 30 ml bottle, 15mg 450x to the consumer level. The Florida Department of Agriculture and Consumer Services tested a random sample and found the product to contain lead levels at 4.7 ppm. When informed of this, Summitt Labs issued an immediate voluntary recall and started an internal investigation. As part of this investigation Summitt Labs had a sample from Batch #730 Lot #K018 tested at an ISO/IEC accredited lab. Lead results were 500 ppb (.5ppm), which is within the legal limits as defined by the State of Florida. However, based on the test from the Florida Department of Agriculture and Consumer Services, Summitt Labs initiated, and will complete, a full recall of Batch #730 Lot #K018 in full cooperation with the FDA and Florida Department of Agriculture and Consumer Services.

Summitt Labs is an inspected and licensed facility under the Florida Department of Food and Agriculture and Consumer Services to produce products containing CBD but the Federal Food and Drug Administration does not consider CBD to be a legal drug or dietary supplement.

Ingestion of KORE ORGANIC Watermelon CBD Oil Batch #730 Lot #K018 containing lead could result in high lead exposure. According to the Florida Department of Health, acute lead poisoning could have signs and symptoms including but not limited to; Pain, Muscle Weakness, Paresthesia, Abdominal Pain, Nausea, Vomiting, Diarrhea, Constipation, Poor appetite, Weight Loss, Symptoms associated with encephalitis, Metallic taste in the mouth, Shock, Hemolysis, and Kidney Damage. To this date, Summitt Labs has not had a call, complaint or report of any adverse effect from the use of this product.

The product labels state that benefits may include, Anxiety Relief, Pain Reduction, Mood Enhancer, Restful Sleep, and may Alleviate Stress. The product is packaged in 30-milliliter bottles; which could come in 9 count displays in Kraft paper packaging. The affected Kore Organic Watermelon CBD Oil lots include Batch#730 Lot#K018. The Product can be identified by the Kore Organic Logo and Kraft Paper Packaging on the 30-milliliter bottle. The product was distributed nationwide by Wholesalers (I.E. Nirvana Kulture and North East Rally), Samples by Sales Personnel, Tradeshow Samples, and by Summitt Labs.

Summitt Labs is notifying its distributors and customers by email, phone, and personal visits to ensure the return of all recalled products. Consumers, distributors, and retailers that have Kore Organic Watermelon CBD Oil Batch #730 Batch #K018, which is being recalled, should stop using the product.

Any consumer with Lot #K018 Batch #730 in their possession are urged to contact Summitt Labs by phone at (833) 810-5673 Monday-Friday 8 a.m. to 5 p.m. EST, or through the website at Any consumer with Lot #K018 Batch #730 should return this product to the place of purchase for a full monetary refund. If that is denied, please contact Summitt Labs at the above number for refund information and any other information regarding this recall. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Contact the FDA

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
  • Side effects and adverse reactions dealing with high levels of lead can be seen at
  • This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.



Product Review: Shea Brands

Upon unboxing, I immediately took notice of this brand’s packaging. It is very unique from other CBD brands. It is full of color and beautiful design and doesn’t appeal to the sometimes default earthy look of many other CBD brands, which is a cool change of pace. Not surprisingly, Shea Brand wants to be known for their packaging and even refers to it in their Instagram bio as “artful, minimal-plastic packaging.” Artful is a great word to describe it. There are so many colors in each package, but it isn’t overwhelming. My husband says men might not be drawn to it, but that’s okay because the brand gives off a “made for women” vibe. They even carry a CBD roll-on for menstrual cramps specifically and sent a tube of it to me. 

600 mg full-spectrum oil 

This product is at the top of my list of the products from Shea Brand, with the transdermal patches coming in a close second. First of all, the packaging is amazing. The box catches your eye immediately. The color is gorgeous, it boasts a blue, almost turquoise hue. The gold lettering and gold hemp leaves add a gentle contrast to the blue without overpowering it. 

The best part though is when you open the box. The box separates into four parts (see the picture below) and each part offers education and information on the product. The box can be easily folded back together, and the innovation of it makes you want to hang onto it forever.

The taste of this oil is powerful, in all of the good ways. These are the ingredients copied directly from the website: Cannabis Sativa Seed Oil (Full Spectrum Hemp Extract), Organic Hemp Seed Oil, Natural Plant Terpenes, Mixed Tocopherols (palm oil-free). Notice there is no MCT oil, palm oil, or any other kind of carrier oil aside from hemp seed oil. That alone makes for a bold flavor but the natural plant terpenes and lack of additional flavoring allow for a rich and earthy hemp flavored oil. You just know the medicine you are getting is potent. 

I would definitely purchase this oil again. 

Transdermal patch

I already mentioned this product is my close-second favorite of the products from Shea Brand that I tried. Each patch dispenses 40 mg of CBD and it can be worn for up to eight hours. I had stomach cramps and I put these patches on and it soothed them for a few hours. 

The most surprising thing though was how the patches impacted my husband. He fractured his C5 vertebrae last year and uses cannabis medicinally to relieve his aches and pains in his neck. He said the patches offered him a lot of relief and he kept it on for the full eight hours. 

The one drawback of the patch was removing it. It was very sticky and hurt a bit to remove. That might just be how it has to be made though in order for the CBD to dispense properly. Either way, a small price to pay for solid relief. 

I would purchase this again. 

CBD menstrual cramp roll on

I was pregnant nearly back-to-back, so I haven’t had a cycle in about 2.5 years. But, weirdly enough, I did have some cycle-like cramps almost as soon as I got this product. I tried it and I’ll be honest, I didn’t feel much relief. That could be for a number of reasons though, I wasn’t really feeling “menstrual cramps” because I didn’t actually get my cycle. It could have been postpartum recovery or something along those lines. I did feel some relief, so I look forward to giving it a more fair shot when I actually get my cycle again. It also smelled fantastic and the oil itself applied very smoothly. It didn’t dispense too much at once either which is nice so you can control how much is coming out. 

I would likely not purchase this again, but I would recommend it to friends! 

Shea Brand CBD Athlete Roller

I used the CBD roller the day after working out on my back. It did help, but it seemed to not be for very long. I typically don’t use roll-ons though so maybe I didn’t apply enough at once. It worked well enough for me to periodically apply it again throughout the day, though. It also smells great and applies very nicely. Pressing down a little bit with the roller on your sore muscles helps kind of massage you also, which is an added benefit. 

I likely wouldn’t purchase this product again but it may work well for someone with different needs! 


StaffStaffApril 30, 2020


A California-based marketer of a supplement consisting mainly of Vitamin C and herbal extracts, David Ching, has agreed to a preliminary order barring him from claiming that it is effective at treating, preventing, or reducing the risk of COVID-19. Ching’s company Whole Leaf Organics has claimed its CBD products to be a treatment for cancer and now claims it is effective in preventing or treating COVID-19.

“There’s no proof that any product will prevent or treat COVID-19 or that any CBD product will treat cancer,” said Bureau of Consumer Protection Director Andrew Smith. “Let’s be clear: companies making these claims can look forward to an FTC lawsuit like this one.”


The complaint alleges that, since at least December 2018, Ching has used his Whole Leaf Organics website to advertise and sell three CBD-containing products, CBD-EX, CBD-RX, and CBD-Max. The first is an ingestible capsule consisting mainly of a combination of cannabidiol and herbal extracts. CBD-RX and CBD-Max are oils composed primarily of CBD and hemp extract. Thirty capsules of CBD-EX retail for $39.99 and CBD-RX and CBD-Max sell for between $75 and $125 per bottle.

Ching advertises all three CBD products as effective cancer treatments. According to the FTC’s complaint, however, Ching does not have the scientific evidence to back up the cancer-treatment claims, and therefore the advertisements are false or deceptive. According to the FTC’s federal district court complaint, since at least December 2018, through Whole Leaf Organics, Ching has advertised and sold Thrive online, with a 50-capsule bottle selling for $36.99.

The federal court complaint states that beginning in or around March 2020 Ching started to market Thrive as an “anti viral wellness booster” that treats, prevents, or reduces the risk of COVID-19. In addition, the FTC alleges that Ching falsely represents that these benefits of Thrive are clinically proven; however, there is no scientific evidence that Thrive or any of its ingredients can treat, prevent, or reduce the risk of COVID-19.

he Commission also has approved the issuance of an administrative complaint containing the same allegations about the health claims Ching made for Thrive and the CBD-based products. In the administrative case, the FTC is seeking an order permanently halting the allegedly deceptive advertising for Thrive, CBD-EX, CBD-RX, and CBD-Max.

The Commission vote authorizing the staff to issue an administrative complaint and seek a temporary restraining order and preliminary injunction was 5-0. The administrative case is scheduled to begin on January 7, 2021.

Tee CorleyTee CorleyMarch 9, 2020


Ben & Jerry’s is well known for making the grooviest ice cream, with flavors like Half Baked and Dave Matthews Band Magic Brownies. So it was no surprise when they announced that CBD-infused ice cream was coming to a freezer near you last year.

So, where’s their hemp-infused flavor?

Ben & Jerry’s announcement was just a few months ahead of a hearing conducted by the Food and Drug Administration (FDA) to discuss legalizing CBD in food and beverages. The ice cream company added a comment to the proposal in favor of legalization at the federal level and encouraged their fans to do the same.

After the 2018 Farm Bill legalized growing and selling hemp, with the stipulation that it should contain no more than 0.3% THC by weight, retailers geared up to infuse everything from eye cream to ice cream with CBD.

The same summer, the FDA approved a CBD-based drug designed to treat rare forms of epilepsy in children. The drug, called Epidiolex, was seen as a symbolic victory for CBD advocates—at first glance.

Instead, this breakthrough blurred the lines further. While advocates assumed this meant CBD would be legal, it instead tossed the cannabinoid categorically into the realm of “pharmaceuticals.”

After all, you can’t add a drug to a food.

In an attempt to shed some light in this murky water, the FDA held its hearing May 31st, 2019. While they received comments from massive food and drink retailers, Ben & Jerry’s among them, they also heard from scientists and medical personnel regarding the safety, guidelines, and suggested regulations of CBD in food and drink.

Ultimately, the FDA stood its ground, denying the use of CBD in food and beverages at this time.

So, if the FDA prohibits CBD food and beverage products, why are some companies still selling it?

The answer lies in the confusion.

While New York City and Los Angeles began cracking down on CBD chefs and mixologists following the FDA’s 2019 news conference, other places, like New Jersey, Pennsylvania, and the rest of California, are refusing to take action until the laws are clarified.

The FDA itself only sporadically enforces the law. While large retailers like Ben & Jerry’s and Whole Foods hold off until CBD food and beverages are federally legalized, smaller retailers are willing to take a chance.

The fact is that CBD is a booming industry. CBD products are expected to reach $16 billion in sales in the U.S. by 2025.

For small time merchants, CBD-infused products are small add-ons that add up. A fruit smoothie with a few milligrams of CBD inflates by $2.95. A CBD chocolate or CBD-infused hemp tea can cost upwards of $5.

When Can You Expect Ben & Jerry’s CBD Ice Cream?

Until CBD food and beverages are legalized at the federal level, we’ll be left spoon-in-hand. You’ll have to look to your local, smaller retailers to soothe your CBD sweet tooth.

Julie AitchesonJulie AitchesonMarch 2, 2020


Hemp industry darling, Charlotte’s Web (OTC:CWBHF), which bills its product line as “the world’s most trusted hemp extract” and was ranked as the top brand by market share for CBD by Nasdaq in 2019, is one of the most recent examples of a large-scale CBD producer to be targeted by a class-action lawsuit.  Litigation ranging in focus from CBD content to marketing (e.g. treatment claims) and stock pricing are on the rise as the Federal Drug Administration issues increasingly tighter restrictions on what is permissible in the world of hemp products. 

In the case of Charlotte’s Web, a class-action lawsuit was filed in the state of California alleging that the company has been marketing its products as “dietary supplements”. This is a designation strictly prohibited by the FDA due to the fact that CBD is an ingredient in an FDA-investigated and approved drug (the anti-epileptic, Epidiolex). The FDA claims that this occurred before any CBD products were marketed as dietary supplements which, under the dietary supplement act, are regulated as food. This timeline distinction is crucial, as companies may have been able to avoid this scrutiny if the dietary supplement designation in their marketing had occurred before CBD came under investigation as a drug by the FDA. Charlotte’s Web and Infinite Products, another big name in CBD also based in Colorado, are both standing by their products and marketing and are determined to fight the litigious wave currently on the rise.

Big companies make big targets, but there are still thousands of products and retail outlets across the country slipping through regulatory loopholes. Which is not to say that they are necessarily angling for this state of affairs to continue. The longer FDA guidelines remain inconclusive and enforcement inconsistent, the more vulnerable companies (particularly smaller operations) become the kind of litigation that could drive them out of business permanently. A recent article on went so far as to say that producers are begging for regulations in order to better protect themselves from these risks.

Though the first lawsuits against CBD product companies date back to the earliest days of the CBD boom, these mostly pertained to an inconsistency between the advertised versus actual potency of products or baldly inflated claims about the products curative capacity, particularly in regards to chronic or life-threatening illnesses. With more definitive censure from the FDA of CBD brands that market themselves as dietary supplements, the field is wide open for litigators to go after any product that has CBD as an ingredient, even if the company is not making unsubstantiated claims or falsifying CBD content. 

This being the case, the hemp industry can expect to see more lawsuits crop up in the weeks and months to come. In the meantime, the FDA continues to play a game of catch up to try to get a handle on hemp and how to ensure consumer safety before even more serious consequences of a still-arbitrarily regulated industry come calling.

Julie AitchesonJulie AitchesonFebruary 26, 2020


Those within the U.S. cannabis industry concerned that President Trump’s trade war with China would present significant difficulties to their sector are finding distraction, if not relief, from an unlikely source– the now-global coronavirus outbreak. As a major supplier of cut-rate hemp fiber and CBD for the world market, China has proven stiff competition for United States’ suppliers both domestically and internationally. The disruption of that supply chain by the coronavirus outbreak means that U.S. producers could finally gain an advantage in domestic and international markets.

This does not mean that there won’t still be a significant downside to slowed or stalled production in China due to the necessity of managing this new, virulent strain of coronavirus identified as COVID-19.  The majority of parts that go into manufacturing vaporizer devices, greenhouse components, LED lighting, and products with Chinese-made steel and aluminum packaging are all sourced in China. Delays in accessing these components could cause serious issues for businesses who rely on their ready availability to meet the demands of consumers in a competitive market. The impact will primarily be felt in the hardware manufacturing sector, as a number of factories supplying vaporizer components are in viral “hot zones” in China, and have been shut down until the virus is brought under control. 

About 90 percent of vaporizing products are manufactured in Shenzen, China, where manufacturers were hit hard by a sharp drop in demand brought on by the vape health scare that began dominating headlines in fall of 2019. This created a glut of vaping hardware, though this glut has been all but exhausted by rising demand due the shutdown of multiple Shenzen factories. How long these facilities will stay offline is unknown, as China remains the epicenter of the disease that the World Health Organization maintains has not yet reached pandemic status.

Some CBD product manufacturers in the U.S. have been quick to pivot their marketing campaigns to promote cannabidiol’s potential as a preventative for coronavirus due to its ability to promote restful sleep (important for immune function) and as a treatment for coronavirus symptoms. While this practice is not yet widespread, it will undoubtedly draw considerable ire and negative attention from the FDA, which has already gotten more serious about cracking down on unsubstantiated health claims in the CBD industry. 

While there may yet be a plausible medicinal use for cannabidiol in the unfolding drama of COVID-19, the industry remains focused on coronavirus’s impact on the market for cannabis and cannabis-derived products. Financial markets across the globe (which as of February 26, 2020 were experiencing a definitive downward turn) have been far from immune from the rising hysteria that a pandemic is inevitable. What this means for the hemp industry, and so many others who trace the origins of their manufacturing pipelines back to China, is a question whose answer may yet be many months down the road.

Julie AitchesonJulie AitchesonFebruary 20, 2020


Amidst concerns on the federal and state levels about violations of FDA regulations regarding CBD products, efforts are being made to allocate more money in the upcoming fiscal year to further define and more stringently enforce CBD laws. President Trump’s proposed budget for fiscal year 2021, should he gain re-election and have the opportunity to present it to Congress, allocates an additional $5 million to the Food and Drug Administration specifically for further regulation and law enforcement pertaining to cannabis and cannabis-derived products. This is the first time that CBD has been mentioned in a federal budget proposal, which suggests that hemp and CBD may be buzzwords cropping up in Presidential debate topics alongside marijuana  leading up to the election.

So where would it leave the future of CBD regulation if Trump is ousted from the White House? Democratic Presidential frontrunners Bernie Sanders and Elizabeth Warren both support legalization of cannabis, with Sanders proposing to legalize within 100 days of his election to office. A historically outspoken proponent of the war on drugs, Joe Biden is sticking to a half-measure platform with a focus on decriminalization, allowing states to regulate hemp for themselves. Michael Bloomberg supports putting legalization in the hands of individual states, though he is personally opposed to legalization. Pete Buttigieg takes the side of veterans with PTSD who often use cannabis and its derivatives to deal with the aftermath of military service, advocating for the decriminalization of all controlled substances. 

As  hemp has yet to be a talking point for presidential candidates, overshadowed as it is by the larger topic of marijuana as a flashpoint for racial justice issues (as criminalization disproportionately affects people of color), what Americans can expect from future budgetary support should a Democrat win office is unclear. What is clear is that the time for comprehensive, consistent regulations and enforcement of cannabis laws on the part of the FDA is long overdue.

 During his January 2020 testimony before the Subcommittee on Health, Committee on Energy and Commerce, and the U.S. House of Representatives, Douglas C. Throckmorton, Deputy Director for Regulatory Programs at the FDA, highlighted the current illegality (per the Food, Drug, & Cosmetic Act)  of interstate commerce of food with CBD additives. He also described in some detail concerns with current CBD marketing tactics that put consumers at risk, such as those products that claim to treat cancer or Alzheimer’s. Throckmorton also identified some particular concerns related to the potential negative health impacts of CBD use, such as liver damage, problematic drug interactions, male reproductive toxicity, and various ill side effects. 

While studies of these impacts are still ongoing and inconclusive, the FDA is clearly intent on taking them, and the future of CBD in the U.S. market, seriously. Whether the President-elect of the United States, whoever he or she may be, manages to pass a budget that supports the FDA in its mission to ensure public safety in regards to CBD is, in many respects, for voters to decide.

Julie AitchesonJulie AitchesonFebruary 19, 2020


Even though the FDA has expressed its displeasure at adding CBD to food, that hasn’t stopped hamburger chains from tossing in some cannabidiol to enhance their burgers. The trend was started last year when on April 20th   of 2019 (yep, that’s 4/20), Carl’s Jr. became the first fast-food chain to sell a CBD burger at one of its franchises in Denver, Colorado. The ambitiously named “Rocky Mountain High: Cheeseburger Delight” was composed of two beef patties, pickled jalapenos, pepper jack cheese, fries, and a Santa Fe sauce infused with 5mg of CBD. And the price? $4.20, of course.

The “Rocky Mountain High”, which was only available for one day, was more of a concept test than a menu change, and given that the location sold more than 100 of them within the first hour and ran out entirely by 4 pm, it was one that the CBD burger passed with flying colors. 

That has sparked Colorado-based Illegal Burger to offer what it calls its biggest differentiator, “its exclusive line of CBD products.” The chain is using the idea of CBD burgers as a way to entice new franchisees. On its website, it states, “As an Illegal Burger franchise owner, you will: Be part of the first CBD restaurant franchise in the U.S.” The company backs its decision by saying, “Cannabinoid, or CBD, is attributed to many health benefits. Recently, the FDA approved of its use to treat two forms of childhood epilepsy, and consumers report it positively impacting anxiety, sleep disorders, and even chronic pain.”

The CBD burger was good for business and, according to reporting by Mike Adams at, even healthier for consumers than a dose of CBD all by itself. Adams cites a study that dosed two separate groups of participants with CBD. One group was placed under fasting conditions (no breakfast), while the other group was fed a high-fat meal. Those who partook of the high-fat meal before consuming a dose of CBD appeared to have a higher absorption rate (as demonstrated by a higher concentration of CBD in their systems) than their fasting counterparts.

So will Carl’s Jr. and Illegal Burgers along with the absorption rate study lead more fast food restaurant chains to jump on the CBD bandwagon in the months and years to come? To a large extent, this depends on how far the FDA goes in doubling down on restrictions prohibiting the addition of CBD to foods and dietary supplements in interstate commerce. Food safety officials in Maine, New York City, Ohio, North Carolina, South Carolina, Florida, and Georgia have all banned the addition of CBD to food.

An April 2019, an  Inverse article on the Carl’s Jr. CBD burger reveals that the Federal Food, Drug, and Cosmetic Act prohibiting any active substance in a pharmaceutical (which, thanks to the advent of  FDA-approved anti-seizure medication Epidiolex, CBD is) from being added to food products further empowers regulators to crack down on the issue. Yet despite the fact that these laws are clearly worded with little room for interpretation, their enforcement still appears to be discretionary, as both the FDA and hemp companies scramble to definitively ensure that the CBD available to the public is pure, potent, and safe.

While private chefs and smaller-scale restaurants are still tempting fate (and upping their prices) to bring CBD and cannabis to the dining public, higher-profile establishments are taking the precautionary principle until federal regulations and law enforcement sort themselves out. Still, given that a National Restaurant Association survey identified CBD and cannabis-infused foods as the top restaurant trend in 2019, there’s still a chance that American consumers might be seeing some “special sauce” on offer at their local drive-thru. 

Julie AitchesonJulie AitchesonFebruary 10, 2020


As more consumers turn to medicinal herbs for their wellness needs or simply to keep current with trendy boho culture, CBD is proving a ubiquitous addition to the scene.  Everyone from CBD industry giants like Charlotte’s Web to boutique brands with witchy cred like Sacred Smoke Herbals is marketing soothing CBD smokes without the addictive chemicals of conventional tobacco products in the form of pre-rolled CBD joints, and consumers are lining up, and lighting up, in response. 

In its forecast of leading trends in 2020, Canna Trading Company featured CBD pre-rolls as a way to consume CBD in its most bioavailable form. (Bioavailability refers to the amount of a consumed substance that actually becomes available for uptake in the body.) When smoked, CBD enters the body through two pathways, the mouth and also the lungs, which deliver CBD directly to the bloodstream. 

Jacob Eppinger, writing for online platform Odyssey, differentiates between CBD pre-rolls, which look exactly like a joint made with THC-rich cannabis, and CBD cigarettes, which are also experiencing a popularity surge. CBD cigarette manufacturers such as Wild Hemp offer smokable CBD without the visual stigma of smoking a joint. CBD manufacturers are eager to cater to the segment of the population that wants to inhale its CBD incognito, without exhaling that signature funky-smelling cloud of smoke. Vendors like Hemp86 have developed smokable CBD products without the funk, and are ranked among the most popular brands on the market. 

Smoking herbs in order to benefit from their medicinal properties is not a new concept. People have long used herbal cigarettes containing such lung-supportive herbs as mullein and coltsfoot, either blended with tobacco or on their own as a way of cutting back on tobacco or making a smoking habit “healthier”. Other relaxing herbs like damiana, lavender, mugwort, and now CBD, are smoked for their non-psychoactive “chill out” effect. 

Pre-rolls provide a cheap, easy way for CBD novices to dip a toe into the cannabidiol world without a huge initial investment. It is possible to buy high-quality hemp flower (which contains the highest potency of CBD) by the gram at a fraction of the cost of oil, though the health benefits appear anything but comparable. Mathew Gold, a staff attorney for the Federal Trade Commission, warns that “simply being free of additives—or, in the case of herbal cigarettes, nicotine, doesn’t make them safer. Any kind of cigarette you smoke has tar and carbon monoxide, which have very real health hazards associated with them.” 

Despite this fact, sales of hemp pre-rolls remain strong. In an article for Hemp Industry Daily, Brightfield Group analyst Bethany Gomez estimates that the smokable hemp market has grown 250 percent since 2017. By 2018, 41 percent of CBD users of the 5,000 surveyed had entirely replaced tobacco with CBD. It remains to be seen whether the pre-roll trend will burn itself out in 2020 or become a new fixture in the CBD consumer’s daily routine, but for now, smokable CBD is sparking plenty of interest.

About Us

The Hemp Market Report will target news from the fast growing worlds of cannabidiol (CBD) and hemp. As a sister site to the Green Market Report, HMR will cover financial stories, but also take a look at lifestyle news as well. The Hemp Market Report will also publish sponsored content as we seek to expand our content offerings.


Recent Tweets

@GreenMarketRpt – 1 day

RT : A big thank you to the participants and attendees of yesterdays Arcview Access Elite, Sponsored by ! #cannabis…

@GreenMarketRpt – 1 day

$CGC ⁦@CanopyGrowth⁩ Delivers Staggering Billion Dollar Net Loss In Fourth Quarter #potstocks…

Back to Top

You have Successfully Subscribed!